表紙:抗潰瘍薬の世界市場:2021年~2028年
市場調査レポート
商品コード
968990

抗潰瘍薬の世界市場:2021年~2028年

Global Antiulcerant Drugs Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円
抗潰瘍薬の世界市場:2021年~2028年
出版日: 2021年07月05日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の抗潰瘍薬市場の成長は、不健康な習慣の増加、発展途上国の人口の増加、多忙なライフスタイル、糖尿病の高い有病率によって牽引されています。

当レポートでは、世界の抗潰瘍薬市場について調査分析し、業界分析、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 世界の抗潰瘍薬市場:調査手法と範囲

第2章 世界の抗潰瘍薬市場:市場定義と概要

第3章 世界の抗潰瘍薬市場:エグゼクティブサマリー

第4章 世界の抗潰瘍薬市場:市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第5章 世界の抗潰瘍薬市場:業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 世界の抗潰瘍薬市場:COVID-19分析

  • 市場に対するCOVID-19の分析
  • COVID-19中の価格動向
  • 需給スペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の抗潰瘍薬市場:種類別

  • イントロダクション
  • 市場規模分析・前年比成長率分析:種類別
  • 市場魅力指数:種類セグメント別
    • プロトンポンプ阻害薬
    • H2受容体拮抗薬
    • 抗生物質
    • 胃粘膜保護薬
    • 制酸剤
    • プロスタグランジンアゴニスト

第8章 世界の抗潰瘍薬市場:疾患別

  • イントロダクション
  • 市場規模分析・前年比成長率分析:疾患別
  • 市場魅力指数:疾患別
    • 胃潰瘍
    • 下肢潰瘍
    • 消化性潰瘍
    • 食道潰瘍
    • 出血性潰瘍
    • 難治性潰瘍
    • その他

第9章 世界の抗潰瘍薬市場:エンドユーザー別

  • イントロダクション
  • 市場規模分析・前年比成長率分析:エンドユーザーセグメント別
  • 市場魅力指数:エンドユーザーセグメント別
    • 病院
    • クリニック
    • 薬局
    • その他

第10章 世界の抗潰瘍薬市場:地域別

  • イントロダクション
  • 市場規模分析・前年比成長率分析:地域別
  • 市場魅力指数:地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋地域
  • 中東・アフリカ

第11章 世界の抗潰瘍薬市場:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • M&A分析

第12章 世界の抗潰瘍薬市場:企業プロファイル

  • Allergan Plc
  • AstraZeneca
  • Daewoong Pharmaceutical
  • Eisai
  • Takeda Pharmaceutical Company
  • Valeant
  • Zydus
  • Shire
  • Meritage Pharma
  • Medfit Biologicals、など

第13章 世界の抗潰瘍薬市場:重要考察

第14章 世界の抗潰瘍薬市場:DataM

目次
Product Code: DMPH2799

Market Overview

The global antiulcerant drugs market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Antiulcerant drugs are a class of drugs or antibacterial agents that are used to treat ulcers especially in the stomach, upper part of the small intestine and other parts of body. Antiulcerant drugs are also gaining popularity in the treatment of diarrhea or address an irritable gastrointestinal tract in patients.

Market Dynamics

The global antiulcerant drugs market market growth is driven by the as increasing unhealthy habits, rising population in the developing countries, swamped lifestyle and high prevalence of diabetes leading to foot ulcers.

Rising awareness about ulcer diseases is expected to drive the growth in the forecast period

There has been rising awareness about ulcer diseases, which has been imparting an increasing momentum to the evolution of the antiulcerant drugs market. The pipeline of promising antiulcerant drugs has been rising over the past few years in various parts of the world. In recent years, the pharmacology of antiulcerant drugs has received considerable attention by pharmaceutical companies, which has helped them develop drugs with better clinical results. The rising incidence of peptide ulcers, especially in people with sedentary lifestyle, is also catalyzing the growth of the global antiulcerant drugs market. The rising acceptance of antacids in anti-ulcer agents among the patient population for symptomatic relief is also a significant boosting the market..

Growing mortality of thrombotic events, especially in tuberculosis patients expected to drive the market growth

There is prevalence of infection with H. pylori in communities with the lack of access to clean water and proper sewage systems. This if untreated may lead to peptic ulcer disease, and antiulcerant drugs play crucial role in there treatment. The growing mortality of thrombotic events, especially in tuberculosis patients, is also likely to accentuate prospects of the antiulcerant drugs market in the coming few years. The rising risk of adverse cardiovascular events related to patients treated with aspirin has fueled the uptake of antiulcerant drugs. In recent years, several pharmaceuticals have been actively working to adopt advanced technologies for manufacturing anatacids. Moreover, they are spending sizeable sums on accelerating their drug pipelines. This will open new, exciting avenues in the global market.

Regulatory obstruction is likely to hinder the market growth

However, various side effects of the drug such as vomiting, nausea, menstrual disorders and stringent government regulations and policies related to drug patents may restrict the growth of the market. Since prediction of occurrence of life-threatening effects is difficult, it is important to correctly consider indications and administer antiulcerant drugs only to patients who truly need it. In addition, patients should be instructed to report unexplained skin eruptions, fever, or general malaise appearing after starting a antiulcerant drugs administration to their attending physician without delay. Doctors also should check for possible adverse effects within the first few weeks after starting an administration by scheduling follow-up consultation sessions.

COVID-19 Impact Analysis

The current utility-owned antiulcerant drugs market is affected mainly by the COVID-19 (Corona Virus Disease) pandemic. There has been delay in most ofthe projects that are in China, the US, Germany and South Korea, as well as companies in these regions are also facing temporaryoperative issues due to absence of site access and constrains in the supply chain. Due to the outburst of COVID-19 in china, Japan and India have shortage of these drugs. Thesse factors are restraning the growth of the market in the forecast period.

Segment Analysis

H2 receptor antagonist segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

H2 receptor antagonist, in full histamine receptor H2 antagonist, any agent that blocks histamine-induced secretion of gastric acid in the stomach. These drugs, which include cimetidine (Tagamet) and ranitidine (Zantac), are used for short-term treatment of gastroesophageal reflux and, in combination with antibiotics, for peptic ulcer.

According to International Foundation for Gastrointestinal Disorders, Inc., the prevalence of gastroesophageal reflux disease (GERD) was 18.1% to 27.8% in North America, 8.8% to 25.9% in Europe, 2.5% to 7.8% in East Asia, 8.7% to 33.1% in the Middle East, 11.6% in Australia, and 23.0% in South America in 2019. GERD is a chronic and highly prevalent disorder that can potentially lead to serious medical complications, and the medical expense involved in the diagnosis, treatment, and management of the disease is significant.

Rising awareness about gastroesophageal reflux disease and acid-peptic disease, availability of treatment options, and management of these diseases, have increased the demand for the treatment of H2-receptor antagonists in developing countries. Governments and other non-profit organizations spread awareness and educate people about gastric acid management through campaigns and educational and clinical workshops. These factors are driving the growth of the market in the forecast period.

The peptic ulcers are expected to dominate the antiulcerant drugs market during the forecast period

Sores that develop on the lining of stomach, esophagus, and intestines are called peptic ulcers. Symptoms of peptic ulcers include vomiting, burning stomach pain, bloating, and food intolerance. Some of the causes of peptic ulcers are stomach infections caused by H. pylori, alcoholism, stomach cancers, usage of anti-inflammatory drugs such as aspirin. Peptic ulcers, if untreated, can cause severe complications such as internal bleeding and perforation in the stomach lining. Lifestyle related factors such as aerated drinks, alcoholism, consumption of fatty food, and stress can cause peptic ulcers. Peptic ulcers can cause severe morbidity in the geriatric population. Hence, increase in this population is a key factor projected to drive the market during the forecast period. Furthermore, increase in patient pool and rise in consumption of drugs such as aspirin, ibuprofen, and other inflammatory drugs are the other factors which drives the market in the forecast period.

Geographical Analysis

North America region holds the largest market share in global antiulcerant drugs

North America region is dominating the global antiulcerant drugs accounted for the largest market share. Rise in awareness about peptic ulcer treatment, usage of antiulcerant drugs, and increase in prevalence of stomach cancer in the region are attributed to the growth of the market in North America. Furthermore, unhealthy lifestyles, high health care expenditure, and sophisticated health care infrastructure are the major factors fueling the growth of the market in the region. In addition, long R&D and approval cycles are required due to capital-intensive nature in North America, which act as a stumbling stone for the growth of the market in the region.

Competitive Landscape

The antiulcerant drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca, Allergan, Daewoong Pharmaceutical, Eisai, Takeda Pharmaceutical Company, Valeant, Zydus, Shire, Meritage Pharma, Medfit Biologicals., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antiulcerant drugs market globally.

Allergan Plc.

Overview: Allergan plc, incorporated in 2013, is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products.

Product Portfolio: The Company's portfolio comprised of pharmaceutical products of specialties for ophthalmologic care, neuromuscular, dermatological and urologic medical devices primarily facial aesthetics products, breast plastic products.

Why Purchase the Report?

  • Visualize the composition of the antiulcerant drugs market segmentation by type, disease, end-user, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in antiulcerant drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of antiulcerant drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global antiulcerant drugs market report would provide an access to an approx. 61 market data table, 61 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Antiulcerant Drugs Market - By Type

  • Proton pump inhibitors
  • H2 receptor antagonists
  • Antibiotics
  • Gastric mucosal protective drugs
  • Antacids
  • Prostaglandin agonists

Global Antiulcerant Drugs Market - By Disease

  • Stomach Ulcers
  • Leg Ulcers
  • Peptic Ulcers
  • Esophageal Ulcer
  • Bleeding Ulcer
  • Refractory Ulcer
  • Others

Global Antiulcerant Drugs Market - By End User

  • Hospital
  • Clinics
  • Pharmaceutical Stores
  • Others

Global Antiulcerant Drugs Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Antiulcerant Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Antiulcerant Drugs Market- Market Definition and Overview

3. Global Antiulcerant Drugs Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market snippet by Disease
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Global Antiulcerant Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising awareness about ulcer diseases
      • 4.1.1.2. Growing mortality of thrombotic events
    • 4.1.2. Restraints:
      • 4.1.2.1. Regulatory obstruction is likely to hinder the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Antiulcerant Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Antiulcerant Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Antiulcerant Drugs Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Proton pump inhibitors *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. H2 receptor antagonists
  • 7.4. Antibiotics
  • 7.5. Gastric mucosal protective drugs
  • 7.6. Antacids
  • 7.7. Prostaglandin agonists

8. Global Antiulcerant Drugs Market - By Disease

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 8.1.2. Market Attractiveness Index, By Disease
  • 8.2. Stomach Ulcers *
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    • 8.2.2. Leg Ulcers
    • 8.2.3. Peptic Ulcers
    • 8.2.4. Esophageal Ulcer
    • 8.2.5. Bleeding Ulcer
    • 8.2.6. Refractory Ulcer
    • 8.2.7. Others

9. Global Antiulcerant Drugs Market - By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
    • 9.1.2. Market Attractiveness Index, By End-User Segment
  • 9.2. Hospital *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Clinics
  • 9.4. Pharmaceutical Stores
  • 9.5. Others

10. Global Antiulcerant Drugs Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Global Antiulcerant Drugs Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of key companies to watch
  • 11.5. List of the company with disruptive technology
  • 11.6. List of start-up companies

12. Global Antiulcerant Drugs Market - Company Profiles

  • 12.1. Allergan Plc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AstraZeneca,
  • 12.3. Daewoong Pharmaceutical
  • 12.4. Eisai
  • 12.5. Takeda Pharmaceutical Company
  • 12.6. Valeant
  • 12.7. Zydus
  • 12.8. Shire
  • 12.9. Meritage Pharma
  • 12.10. Medfit Biologicals

LIST NOT EXHAUSTIVE

13. Global Antiulcerant Drugs Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us